TrialPhase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
Trial details
- Registry ID
- NCT01838395
- Phase
- Phase 2
Drug research
BL-8040
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML PatientsNCT01838395 | BLRX | Phase 2 | Completed | 2016-03Actual |
| Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer PatientsNCT02826486 | BLRX | Phase 2 | Completed | 2022-09-06Actual |
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
Trial details
- Registry ID
- NCT02826486
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |